Published • loading... • Updated
Glucotrack CEO explains tech behind long-term CBGM implant
Summary by Drug Delivery Business
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Glucotrack CEO explains tech behind long-term CBGM implant
Glucotrack 3-year continuous blood glucose monitor (CBGM) Glucotrack (Nasdaq:GCTK) has made great strides over the past several years as it advances its implantable continuous blood glucose monitor (CBGM). Rutherford, New Jersey-based Glucotrack’s device features no on-body external component. The company aims to offer it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike tradi…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
